Targeting aberrant β-1,4-galactosyltransferase 1 (B4GALT1) activity represents an unexplored therapeutic avenue for pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene B4GALT1 and pancreatic ductal adenocarcinoma.